您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Nicotinamide(Vitamin B3)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Nicotinamide(Vitamin B3)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Nicotinamide(Vitamin B3)图片
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
500mg电议
1g电议
5g电议

产品介绍
烟酰胺 (Vitamin B3) 是一种维生素 B3 或烟酸,可在体外抑制 sirtuin 2 (SIRT2) 活性,EC50 为 2 μM. Nicotinamide (Vitamin B3) 抑制高达 90% 的黑色素瘤细胞数量并增加细胞 NAD+、ATP、ROS 水平。烟酰胺(维生素B3)在体内抑制肿瘤生长,提高黑色素瘤小鼠的存活率,可用于黑色素瘤等皮肤癌的研究。

Animal experiment:

DM is induced via a single intraperitoneal (i.p) injection of nicotinamide (110 mg/kg/body weight) dissolved in normal saline 15 min prior to streptozotocin (STZ) (55 mg/kg/body weight) injection, which is dissolved in a freshly prepared 0.1mol/Lcitrate buffer (pH 4.5). These injections are given following an overnight fast. Control rats (n=6) are injected with the same amount of solvent. In order to prevent hypoglycemia in the first 24 h following STZ injection, rats are allowed to have free access to water with 5% dextrose (D5W). Three days after STZ-nicotinamide injection, rats with FBG levels greater than 7.0 mM are considered as diabetic.

产品描述

IC50: N/A

Nicotinamide is an inhibitor of poly(ADP-ribose) polymerase (PARP-1) enzymes. Poly(ADP-ribose) polymerase-1 (PARP-1) is found as a DNA repair enzyme. The excessive activation of PARP-1, such as ischemia and trauma, can deplete cellular nicotinamide adenine dinucleotide as a substrate and leads to brain cell death eventually.

In vitro: Previous findings suggested that nicotinamide had a protective effect against PARP-1-induced astrocyte death. The transporter-mediated uptake of nicotinamide, which was extracellular pH-sensitive and common to N-methylnicotinamide, was found to be critical for prevention of PARP-1-triggered cell death [1].

In vivo: Type 2 diabetes was induced in Wistar rats by streptozotocin followed by nicotinamide. Test compounds and standard treatment were continued for 15 days. Results showed that there was significant normalisation of liver antioxidant enzymes compared to diabetic rats, suggesting all the tested compounds were beneficial in reducing oxidative stress [2].

Clinical trial: Previous clinical trials showed nicotinamide was well tolerated. Phase 1 showed a dose-response relation for proportional change in frataxin protein concentration. Phases 2 and 3 showed daily dosing resulted in a sustained and significant upregulation of frataxin expression [3].

References:
[1] Suzuki E,Okuda H,Nishida K,Fujimoto S,Nagasawa K. Protective effect of nicotinamide against poly(ADP-ribose) polymerase-1-mediated astrocyte death depends on its transporter-mediated uptake. Life Sci.2010 Apr 24;86(17-18):676-82.
[2] Yogendra Nayak, Venkatachalam Hillemane,Vijay Kumar Daroji,B. S. Jayashree,andM. K. Unnikrishnan. Antidiabetic Activity of Benzopyrone Analogues in Nicotinamide-Streptozotocin Induced Type 2 Diabetes in Rats. Scientific World Journal. 2014; 2014: 854267.
[3] Libri V,Yandim C,Athanasopoulos S,Loyse N,Natisvili T,Law PP,Chan PK,Mohammad T,Mauri M,Tam KT,Leiper J,Piper S,Ramesh A,Parkinson MH,Huson L,Giunti P,Festenstein R. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study. Lancet.2014 Aug 9;384(9942):504-13.